Metabolic dysfunction-associated steatotic liver disease (MASLD), also known as fatty liver disease, is a chronic liver condition that affects nearly 1 in 3 people worldwide. It is closely linked to obesity, type 2 diabetes, and metabolic syndrome. Unchecked, it can progress to a more severe form of disease called Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Prognosticating the risk of disease progression in MASLD and MASH has traditionally involved liver biopsy, a process that involves removing a tissue sample with a hollow needle and then examining the sample under a microscope to diagnose and stage disease. However, biopsy has many limitations. Additionally, drug development for MASLD and MASH has proceeded slowly in part due to a reliance on liver biopsy to determine drug efficacy.

Recently, increasing evidence is suggesting that non-invasive options, for example, imaging examinations along with blood tests that assess likelihood of disease progression such as the Enhanced Liver Fibrosis (ELF) Test, may effectively reduce the need for the more invasive alternative. Key experts in MASLD and MASH share their perspectives about how clinical evidence supports a shift in the way patients with MASLD and MASH could be evaluated in clinical practice and in research.

Host Matt Gee, Director of Collaborations and External Engagement at Siemens Healthineers, is joined by Prof. William Rosenberg, Deputy Director of the Institute for Liver and Digestive Health at University College London as well as Dr. Veronica Miller, Director of the Forum for Collaborative Research at the University of California, Berkeley School of Public Health; Dr. Arun Sanyal, Professor of Medicine, Physiology, and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University; and Dr. Michelle Long, International Medical Vice President of Metabolic Dysfunction-Associated Steatohepatitis at Novo Nordisk and Associate Professor in the Section of Gastroenterology and Hepatology at Boston University.

What you’ll learn in this episode:

• Liver biopsy creates several obstacles for patients and has limitations
• Drug development faces challenges by the reliance on biopsy as a measure of treatment effectiveness
• Non-invasive tools may be suitable alternatives to liver biopsy both in clinical practice and in drug development

Connect with Matt Gee

• LinkedIn

Connect with Veronica Miller

• LinkedIn

Connect with William Rosenberg

• LinkedIn

Connect with Michelle Long

• LinkedIn

Connect with Arun Sanyal

• VCU.edu

Hosted on Acast. See acast.com/privacy for more information.

A reversible liver condition is the fastest growing cause of liver transplantation in Western countries: Metabolic dysfunction-associated steatotic liver disease—or MASLD—affects patients worldwide. It’s characterized by excessive fat accumulation in the liver and can progress into more severe forms of liver disease, potentially resulting in fibrosis, cirrhosis and liver failure.

Risk factors for developing liver disease include obesity, insulin resistance, type 2 diabetes, and metabolic syndrome. Genetics, unhealthy dietary habits, and a sedentary lifestyle can also play significant roles in its development. Diagnosis typically involves imaging examinations along with blood tests that assess liver function and rule out other causes of liver disease.

Disease management focuses on lifestyle modifications such as diet and exercise, though new medications are now being prescribed to slow and potentially reverse this condition. Regular monitoring of disease progression is also crucial for successful treatment.

In this episode, experts in the field of liver disease address the progress happening in the recognition, diagnosis and treatment of the disease.

Host Matt Gee, Director of Collaborations and External Engagement at Siemens Healthineers, is joined by Dr. Michelle Long, International Medical Vice President of Metabolic Dysfunction-Associated Steatohepatitis at Novo Nordisk and Director of Clinical Research for the Section of Gastroenterology and Hepatology at Boston University; Dr. Arun Sanyal, Professor of Medicine, Physiology, and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University; and Michael Betel, President and Founder of the Fatty Liver Alliance.

What you’ll learn in this episode:

• One of the biggest obstacles to diagnosing MASLD before it progresses stems from the lack of visibility and awareness of the disease
• MASLD is a reversible disease when caught in time
• MASLD is more complex than a patient’s diet or lifestyle—metabolic dysfunction plays a role
• Non-invasive testing has become an important tool in advancing patient care

Connect with Matt Gee

• LinkedIn

Connect with Michelle Long

• LinkedIn

Connect with Arun Sanyal

• VCU.edu

Connect with Michael Betel

• LinkedIn

Hosted on Acast. See acast.com/privacy for more information.

Radiotherapy plays a vital role in cancer treatment. In Europe alone, incidents of cancer are projected to rise around 20% by 2040, mainly due to an increasingly aging population. It’s numbers like these that emphasize the importance of pushing boundaries in radiotherapy.

With AI-optimized workflows, it’s possible to speed up treatment planning and ensure highly personalized therapies and technology like auto contouring can protect healthy organs during irradiation by means of AI. This implementation, however, is often met with challenges like staff shortages and inconsistencies with data collection, highlighting the need for more efficient implementation strategies.

In this episode, experts in the fields of radiotherapy and cancer treatment address the amazing headway being made in the world of radiotherapy as well as some of the key roles that current technology can play in the future.

Host Sasa Mutic, President of Radiation Oncology Solutions at the Varian Business Area of Siemens Healthineers, is joined by Valery Lemmens, a member of the Board of Directors at Maastro Radiotherapy Clinic in the Netherlands and creator of the Dutch Cancer Atlas; as well as Joost Verhoeff, radiation oncologist and professor of radiotherapy at Amsterdam University Medical Center; and Indrin Chetty, Vice Chair and Director of the Division of Medical Physics at Cedars-Sinai in Los Angeles.

What you’ll learn in this episode:

• By using a digital twin, medical professionals can review existing health records and continually compare that information with patient data
• With adaptive radiotherapy, radiation dosages can be tailored to circumstances like tumor size, type, and position and proximity to vital organs
• The Dutch Cancer Atlas interprets and publishes data in a context that increases awareness of regional differences in cancer incidents
• The unique role that data plays in the advancement of cancer care
• The deep troves of data that already exist within radiotherapy departments can play a key role in the integration of AI into cancer treatments
• Widespread availability of data creates the opportunity for automated treatment planning and outcome prediction

Connect with Sasa Mutic

• LinkedIn

Connect with Valery Lemmens

• LinkedIn

Connect with Joost Verhoeff

• LinkedIn

Indrin Chetty

• LinkedIn

Hosted on Acast. See acast.com/privacy for more information.

With significant disparities in diagnosis, treatment, and funding when compared to men, women’s health has long been underserved. These gaps affect not only individual health outcomes, they also have societal and economic implications which are highlighted by a recent report by the World Economic Forum and The McKinsey Health Institute which addresses a $1 trillion dollar opportunity to improve lives and economies by mitigating these disparities.

Factors like societal perception, clinical practice, and financial investment all play an important part in women’s health. Addressing the gender health gap and overcoming issues like the misdiagnosis of diseases in women, increasing women’s representation in clinical trials, and advocating for greater financial investment in women’s health are all crucial steps in building a more equal healthcare system for all.

Today, we’re joined by board members of the World Economic Forum’s Global Alliance for Women’s Health to discuss how building a more equitable healthcare system can drive meaningful change, improve healthcare for women, and create access to significant economic potential worldwide.

In this episode, host Elisabeth Staudinger, Member of the Managing Board of Siemens Healthineers, is joined by fellow World Economic Forum’s Global Alliance for Women’s Health board members Nadia Fettah, Minister of Economy and Finance for the Government of Morocco and Shyam Bishen, Head of the Centre for Health & Healthcare at the World Economic Forum.

What you’ll learn in this episode:

• Despite living longer, women spend 25% more time in poor health than men
• Women are twice as likely to be misdiagnosed after having a heart attack than men. Along with misdiagnosis and premature discharge, female cardiac patients are also less likely to be prescribed secondary prevention measures after experiencing a cardiac event
• How the Global Alliance for Women's Health is pooling together efforts in research, regulation and funding to close the gender healthcare gap
• Success stories that give hope on the path to healthcare equality

Connect with Elisabeth Staudinger

• LinkedIn

Connect with Nadia Fettah

• LinkedIn

Connect with Shyam Bishen

• LinkedIn

Hosted on Acast. See acast.com/privacy for more information.

Sepsis, originally known as blood poisoning, is a life-threatening medical emergency. Tune in to learn about the complexities of sepsis diagnosis, the role of lactate and procalcitonin levels, and the global health challenge it poses. Hear from experts and a sepsis survivor about the advancements in identifying and managing this critical condition.

Sepsis is the body’s extreme response to an infection. It occurs when a pre-existing infection triggers a chain reaction throughout a person's body. Sepsis can be difficult to diagnose because patients present different symptoms, and their observation can be subjective. According to the Global Sepsis Alliance, the disease contributes to approximately one in five deaths worldwide and in the United States alone; it stands as the leading cause of death in hospitals, leading to one in three hospital fatalities. Compounding these mortality rates is a rise in antibiotic and antimicrobial resistance due to overuse or misuse.

Today, we’re joined by experts in the field of diagnostics and critical care as well as a sepsis patient and advocate in order to more acutely understand the disease, its diagnosis, and the advancements in the field.

In this episode, host Ranga Sampath, Senior Vice President and Head of the Center for Innovation in Diagnostics at Siemens Healthineers and Member of the Board of the Sepsis Alliance, welcomes:

• Heike Spreter-Krick a sepsis survivor who is now a patient advocate working with the Global Sepsis Alliance
• Patti DeJuilio, Director of Respiratory Care and Diagnostic Services at Northwestern Medicine Central DuPage Hospital in Winfield, Illinois
• Dr. Eric Gluck, Director of Critical Care Services at Swedish Hospital and professor of medicine at Finch University of Health Sciences at The Chicago Medical School
• Mervyn Singer, professor of intensive care medicine at University College London

What you’ll learn in this episode:

• The timing of diagnosis and treatment is critical because sepsis creates oxygen deprivation in the cells.
• Risk factors like age and comorbidities can increase the likelihood of a patient developing sepsis.
• The biomarker procalcitonin can be used as an identifier for sepsis infection.
• Lactate levels, a chemical naturally produced by the body during times of stress, can be used as one indicator among others that a patient may be experiencing sepsis.
• In the UK, the National Early Warning Score helps closely monitor patients at risk for developing sepsis.
• IV antibiotics have long been the gold standard for sepsis treatment, but they are at risk of overuse and misuse.
• For many patients, surviving a sepsis infection is just the beginning of a long road to recovery.

Connect with Ranga Sampath

• LinkedIn

Connect with Heike Spreter-Krick

• Instagram

Connect with Patti DeJuilio

• LinkedIn

Connect with Mervyn Singer

• LinkedIn

Hosted on Acast. See acast.com/privacy for more information.

Regular exercise is one of the most effective methods to keep the heart healthy and efficient. In rare cases, however, there are reports of athletes collapsing mid-game due to cardiac arrest. And while exercise is generally also a key part of the rehabilitation process for those who’ve experienced cardiac events, caution should still be taken. This is where physician input is important, and where testing and regular monitoring can be implemented to reduce the risk of further events.

Today, we’re joined by experts in the fields of sports cardiology and exercise physiology, as well as an athlete with firsthand experience in the matter, to draw attention to the topic of cardiac health and how it pertains to sports medicine.

In this episode, host Myra Cocker, Assistant Professor of Cardiology at Houston Methodist Hospital and Global Director of Clinical Science for Cardiovascular Ultrasound at Siemens Healthineers, welcomes Dr. Jonathan Kim, Associate Professor and Founding Director at Emory University Sports Cardiology and Team Cardiologist for Georgia Tech, the Atlanta Falcons, Hawks, and Braves; as well as Dr. Dominique Hansen, Professor of Rehabilitation and Exercise Physiology in Cardiometabolic Diseases at Universiteit Hasselt in Belgium and Secretary of the European Association of Preventive Cardiology; and retired professional soccer player and cardiology patient Daniel Engelbrecht.

What you’ll learn in this episode:

• How cardiac risk can affect older and younger elite athletes differently
• Cardiac events can stem from myocarditis, caused by an infectious disease.
• Red flag symptoms when it comes to cardiac events while exercising, including intense chest pressure or loss of consciousness
• The use of Automated External Defibrillators is a critical first response strategy in the event of cardiac arrest.
• Implementation of an exercise program can be essential when treating a patient who has experienced, or is at risk for, cardiovascular disease.
• For patients who have suffered from major cardiac events, their timeline for return to sports or intense physical activity is heavily dependent on a number of individual factors.

Connect with Myra Cocker

• LinkedIn

Connect with Jonathan Kim

• LinkedIn

Connect with Dominique Hansen

• LinkedIn

Connect with Daniel Engelbrecht

• LinkedIn

Hosted on Acast. See acast.com/privacy for more information.

Every year, more than 12 million people suffer from strokes. With 6.5 million dead and many left with permanent disability, it is one of the leading causes of death and disability worldwide.

Today, we’ll learn about the stroke pathway and secondary stroke risk as well as the underlying diseases that are connected to stroke and how they can be identified and treated.

In this episode, host Wiebke Plenkers, product line head for ON THE SPOT, Siemens Healthineers global mobile CT solutions, is joined by Mira Katan, MD, head of Stroke Unit and deputy head of Acute Neurology at University Hospital Basel in Switzerland and Carlos Molina, MD, head of Neurology Section and director of Stroke Unit at Barcelona’s Vall d’Hebron Research Institute.

What You’ll Learn in This Episode:

• The pathway for an incoming patient after it is determined that they are suffering from a stroke
• Determining the type and severity of the stroke is an important deciding factor for successful treatment
• Modern imaging techniques support in the identification between an ischemic or hemorrhagic stroke
• Secondary stroke events are a significant risk for many stroke patients
• Educating patients is key in preventing secondary stroke events
• Implementation of telemedicine is just one of the advances that might improve outcomes for stroke patients in the future

Connect with Wiebke Plenkers

•LinkedIn

Connect with Mira Katan

•LinkedIn

Connect with Carlos Molina

•LinkedIn

Hosted on Acast. See acast.com/privacy for more information.

In medical imaging, there is a constantly growing gap between the need for diagnostic imaging and the availability of specialist staff. At the same time, groundbreaking developments in the field of artificial intelligence continue to transform the face of the imaging field as we know it. In fact, AI is currently being used as an efficient and cost-reducing solution to a variety of industry challenges.

Today, you’ll hear several panel conversations discussing generative AI in radiology, recorded live at the European Congress of Radiology. Held this year in Vienna, the ECR is one of the leading events in radiology as well as one of the world’s largest international meetings of radiology professionals, radiographers, physicists, and industry representatives.

In this episode, host Fabian Schoeck, Head of Global Product Management for Artificial Intelligence Products at Siemens Healthineers, is joined by Dr. Johannes Haubold, Senior Physician for Clinical AI Integration at University Hospital Essen and Isabelle Ayx, a Senior Radiologist at University Medical Center Mannheim, all based in Germany.

What You’ll Learn in This Episode:

• The potential and the limitations of generative AI in radiology
• AI can be used to help with early detection
• Generative AI can transform clinical workflows
• How can AI can pave the way for more accurate and efficient diagnostics
• Artificial intelligence can process massive amounts of data, allowing for huge advantages to research
• What’s coming next in AI development for the radiology field

Connect with Fabian Schoeck

• LinkedIn

Connect with Johannes Haubold

• LinkedIn

Connect with Isabelle Ayx

• LinkedIn

Hosted on Acast. See acast.com/privacy for more information.